Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Finished Goods: 2019-2025

Historic Finished Goods for CorMedix (CRMD) over the last 3 years, with Sep 2025 value amounting to $12.8 million.

  • CorMedix's Finished Goods rose 1233.22% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year increase of 1233.22%. This contributed to the annual value of $3.0 million for FY2024, which is N/A change from last year.
  • Per CorMedix's latest filing, its Finished Goods stood at $12.8 million for Q3 2025, which was up 285.98% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Finished Goods ranged from a high of $12.8 million in Q3 2025 and a low of $245,668 during Q2 2021.
  • In the last 2 years, CorMedix's Finished Goods had a median value of $2.1 million in 2025 and averaged $3.4 million.
  • In the last 5 years, CorMedix's Finished Goods slumped by 39.79% in 2021 and then spiked by 1,233.22% in 2025.
  • Over the past 3 years, CorMedix's Finished Goods (Quarterly) stood at $245,668 in 2021, then reached $3.0 million in 2024, then soared by 1,233.22% to $12.8 million in 2025.
  • Its Finished Goods stands at $12.8 million for Q3 2025, versus $3.3 million for Q2 2025 and $2.1 million for Q1 2025.